Don Evans, chief executive of Advanced Medical Solutions, says business partners have shown 'phenomenal interest' in its acquisition of MedLogic, while two new development deals should help AMS reach breakeven this year. William Davidson reports.

The recent acquisition of MedLogic affords techMARK-listed AMS access to its innovative 'wound glue' technology. Evans says he is flying out to the US after the annual meeting on Tuesday to talk to the partners about the technology. 'Once word got out', he said, 'they were all phenomenally interested. I have meetings lined up with six of them already. They all want to start talking about the possibilities'.

MedLogic's technology uses a superglue-like product to stick wounds together, rather than stitches or sutures. The glues are ideally suited to areas where scars can be unsightly, such as in facial surgery or Caesarean deliveries.

'We have relationships in place with the major woundcare manufacturers', claims Evans. 'We work with their R&D departments to develop new products for them'.

Separately, Evans has signed two deals which were flagged up at the time of the results earlier in the month. AMS has entered into development agreements with two international healthcare companies to develop products incorporating both its silver fibre technology licensed from Noble Fiber Technologies Inc, and also its seaweed-based alginate which helps wounds heal faster.

The shares picked up 9 per cent to 9p, capitalising AMS at £8.4 million. When the company reaches breakeven, scheduled for the fourth quarter of this year, Evans says 'the shares will really start to move'.